Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

71
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
71
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.6K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.6K
Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

4.4K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
4.4K
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

118
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
118
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

55
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
55
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

9.2K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
9.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Do We Always Need a New Preference Study? A Scoping Review of Promising Research Areas for Meta-Analyses and Benefit Transfers of Patient Preference Studies.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2025
Same author

Designing a Patient Preference Study on Subcutaneous Medical Devices: Incorporating Health Authority Scientific Advice and Patient Perspectives.

Therapeutic innovation & regulatory science·2025
Same author

A constrained optimum adaptive design for dose finding in early phase clinical trials.

Journal of biopharmaceutical statistics·2024
Same author

A comparative analysis of potential aerosol exposure in a wide-body aircraft cabin using tracer gas and fluorescent particles.

The International journal of ventilation·2024
Same author

Development of a disease-specific health utility score for chronic obstructive pulmonary disease from a discrete choice experiment patient preference study.

International journal of technology assessment in health care·2024
Same author

Cardiac copper content and its relationship with heart physiology: Insights based on quantitative genetic and functional analyses using BXD family mice.

Frontiers in cardiovascular medicine·2023
Same journal

A novel Milstein-stochastic epidemiologically-informed neural network for approaching epidemic dynamics: Application to Mpox disease.

Computer methods and programs in biomedicine·2026
Same journal

Accounting for approximation errors using surrogate-based parameter estimation of cardiac mechanics digital twins.

Computer methods and programs in biomedicine·2026
Same journal

Facial iPPG heatmap patterns based on period-aware autoencoder show association with carotid atherosclerosis towards non-contact hemodynamic assessment.

Computer methods and programs in biomedicine·2026
Same journal

Explainable machine learning models predict liver fibrosis risk and outcome in the general population: Development and multi-cohort external validation.

Computer methods and programs in biomedicine·2026
Same journal

Evaluation of surrogate endpoints for survival outcomes using the surrogate package in R.

Computer methods and programs in biomedicine·2026
Same journal

Relative spectral and frication-based descriptors as numerical indicators of place of articulation shifts in fricatives produced by Polish children.

Computer methods and programs in biomedicine·2026
See all related articles

Related Experiment Video

Updated: Nov 17, 2025

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

3.0K

Model based dose personalization in clinical trials.

Kabir Soeny1, Barbara Bogacka1, Byron Jones2

  • 1School of Mathematical Sciences, Queen Mary University of London, UK.

Computer Methods and Programs in Biomedicine
|February 15, 2021
PubMed
Summary
This summary is machine-generated.

This study introduces a new method for optimizing drug doses during clinical trials, ensuring patients receive the intended drug exposure while accurately estimating pharmacokinetic profiles. The algorithm achieves high efficiency, minimizing over- and under-dosing for personalized medicine development.

Keywords:
D-optimal designDose optimizationPersonalized medicinePharmacokinetic estimationRandomized concentration-controlled trialsTarget drug concentration

More Related Videos

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.7K
Evaluating Regional Pulmonary Deposition using Patient-Specific 3D Printed Lung Models
07:56

Evaluating Regional Pulmonary Deposition using Patient-Specific 3D Printed Lung Models

Published on: November 11, 2020

4.5K

Related Experiment Videos

Last Updated: Nov 17, 2025

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform
07:57

Positron Emission Tomography-based Dose Painting Radiation Therapy in a Glioblastoma Rat Model using the Small Animal Radiation Research Platform

Published on: March 24, 2022

3.0K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

20.7K
Evaluating Regional Pulmonary Deposition using Patient-Specific 3D Printed Lung Models
07:56

Evaluating Regional Pulmonary Deposition using Patient-Specific 3D Printed Lung Models

Published on: November 11, 2020

4.5K

Area of Science:

  • Pharmacokinetics and Drug Development
  • Personalized Medicine
  • Clinical Trial Optimization

Background:

  • Personalized medicine aims to tailor therapies to individual patients.
  • Therapeutic drug monitoring is crucial for drugs with narrow therapeutic indices but is not feasible for drugs in early development.
  • Limited pharmacokinetic data hinders dose optimization for investigational drugs.

Purpose of the Study:

  • To present a novel methodology for optimizing drug dose regimens during pharmacokinetic studies.
  • To ensure drug blood concentrations remain within a target range for each subject.
  • To facilitate individualized dosing and accurate pharmacokinetic estimation.

Main Methods:

  • Development of an algorithm for explicit dose regimen optimization.
  • Integration of dose individualization with pharmacokinetic estimation.
  • Application during the course of pharmacokinetic studies.

Main Results:

  • The algorithm successfully estimates pharmacokinetic profiles while individualizing doses.
  • Achieved an average relative efficiency of 97% with a standard deviation under 5%.
  • Demonstrated ability to minimize subject over- and under-exposure to the therapy.

Conclusions:

  • The methodology ensures correct dosing and intended drug exposure for clinical trial subjects.
  • Facilitates simultaneous estimation of drug pharmacokinetic profiles.
  • Applicable to randomized concentration-controlled trials requiring target concentration maintenance.